Glaxo's Witty Touts Innovation as Best Defense for Drug Prices

  • Innovative drugs may be best defense against payer pressure
  • Company won't chase expensive deals for late-stage assets

As the pharmaceutical industry faces mounting scrutiny over drug pricing, GlaxoSmithKline Plc Chief Executive Officer Andrew Witty touted innovation as the best defense and pledged to highlight a product pipeline next month that would help withstand pressure from payers.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.